Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer

Abstract Background Treatment with regorafenib, a multiple-kinase inhibitor, to manage metastatic colorectal cancers (mCRCs) shows a modest improvement in overall survival but is associated with severe toxicities. Thus, to reduce regorafenib-induced toxicity, we used regorafenib at low concentration...

詳細記述

書誌詳細

出版年:	Journal of Experimental & Clinical Cancer Research
主要な著者:	Prachi Bajpai, Sumit Agarwal, Farrukh Afaq, Sameer Al Diffalha, Darshan S. Chandrashekar, Hyung-Gyoon Kim, Abigail Shelton, C. Ryan Miller, Santosh K. Singh, Rajesh Singh, Sooryanarayana Varambally, Ganji Purnachandra Nagaraju, Ashish Manne, Ravi Paluri, Moh’d Khushman, Upender Manne
フォーマット:	論文
言語:	英語
出版事項:	BMC 2024-07-01
主題:	Colorectal cancer JAK/HDACi Regorafenib Combination therapy Toxicity
オンライン･アクセス:	https://doi.org/10.1186/s13046-024-03106-8